Hansoh signs $690M ADC pact with fellow Chinese biotech Biotheus
Biotheus Expanded Their Partnership with Hansoh Pharma for Developing EGFR/cMET Bispecific Antibody-Drug Conjugates
GSK enters exclusive license agreement with Hansoh for HS-20093
GSK enters exclusive license agreement with Hansoh for HS-20089
Antengene Corporation Limited, a leading innovative, commercial-stage global biopharmaceutical company, and Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma), a leading innovation-driven pharmaceutical company, announced the entrance into a collaboration agreement between Antengene and Hansoh Pharma for the commercialization of Xpovio in the mainland of China.
Shanghai ,July 20, 2023 – Hansoh Pharma(03692.HK?, a leading innovation-driven pharmaceutical company in Greater China, today announced that China’s National Medical Products Administration (NMPA) has accepted for reviewing a New Drug Application (NDA) for oral ibrexafungerp tablets for the treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (VVC) in Chinese mainland. The application is based on positive results from Phase 3 studies in which ibrexafungerp successfully achieved statistically significant superiority over placebo for the primary and key secondary study endpoints.
LONDON--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming peoples’ lives by silencing diseases through precision engineered medicines, today announced that it will receive a $4.0 million cash payment from Hansoh Pharmaceutical Group Company Limited (“Hansoh”) following the achievement of two undisclosed preclinical milestones.
On June 30, Hansoh Pharma's Saint Luolai(Pegmolesatide Injection) ,the global unique once-monthly peptide-based highly specific EPO receptor activator?PERA?,was granted approval by the National Medical Products Administration (NMPA) for marketing. This approval is for the treatment of anemia due to Chronic Kidney Disease (CKD), including adult non-dialysis patients who are not receiving Erythropoiesis Stimulating Agent (ESA) and adult dialysis patients receiving short-acting Erythropoietin (EPO). Saint Luolai now becomes the seventh innovative drug from Hansoh Pharma to receive marketing approval.
BOSTON and SEONGNAM, South Korea, July 5, 2023 /PRNewswire/ -- TiumBio Co., Ltd. (KOSDAQ: 321550), a clinical-stage biopharmaceutical company focusing on discovering and development innovative therapeutics for patients with rare and incurable diseases, and Hansoh Pharmaceutical Group Co., Ltd. (SEHX: 3692), a leading biopharmaceutical company, announced that the China National Medical Products Administration (NMPA) approved Hansoh's Investigational New Drug (IND) application for clinical study of HS-10518 (also known as TU2670), the management of moderate to severe pain associated with endometriosis .